{"id":5748,"date":"2015-07-15T16:32:01","date_gmt":"2015-07-15T14:32:01","guid":{"rendered":"http:\/\/dev-leitat-projects-blog.pantheonsite.io\/?p=5748"},"modified":"2025-02-10T11:30:31","modified_gmt":"2025-02-10T11:30:31","slug":"toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014","status":"publish","type":"post","link":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/","title":{"rendered":"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS – Colaboraci\u00f3n 2014"},"content":{"rendered":"

\"Toxcab\"
\nEl proyecto de investigaci\u00f3n aplicada ToxAb tiene por objetivo principal generar una ventaja competitiva en el \u00e1rea de la terapia oncol\u00f3gica mediante la validaci\u00f3n y el uso de la tecnolog\u00eda de conjugaci\u00f3n de agentes citot\u00f3xicos y material gen\u00e9tico (PPRHs) a anticuerpos monoclonales. Por tanto, el proyecto combina el potencial de tres l\u00edneas de investigaci\u00f3n punteras:<\/p>\n

 <\/p>\n

    \n
  1. \n
      \n
    1. La utilizaci\u00f3n de nuevos anticuerpos monoclonales desarrollados por LEITAT contra dianas implicadas en el desarrollo tumoral de la familia del epidermal growth factor receptor (Her1\/EGFR i Her2\/ErbB2)<\/li>\n
    2. El uso de una tecnolog\u00eda puntera en la conjugaci\u00f3n de citot\u00f3xicos desarrollado internacionalmente por la empresa ProteoDesign,<\/li>\n
    3. La utilizaci\u00f3n de material gen\u00e9tico basado en la tecnolog\u00eda del silenciamiento por PPRHs desarrollado y validado por LEITAT dirigido contra dianas ampliamente validadas a nivel de terapia antitumoral.<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n

      El proyecto se inscribe en el entorno de un nuevo paradigma por el que actualmente apuestan todas las grandes empresas farmac\u00e9uticas a nivel internacional: los ADC. Adicionalmente, combina el potencial de investigaci\u00f3n llevada a cabo en centros de investigaci\u00f3n espa\u00f1oles y universidades norteamericanas (Universidad de Princeton y Universidad Rockefeller) a trav\u00e9s de dos entidades espa\u00f1olas.<\/p>\n

      La colaboraci\u00f3n se ha establecido entre un spin-off de reciente creaci\u00f3n (ProteoDesign S.L.) que ha desarrollado una tecnolog\u00eda revolucionaria de conjugaci\u00f3n, con un Centro Tecnol\u00f3gico (LEITAT) con amplia experiencia en el campo de los anticuerpos y en la caracterizaci\u00f3n funcional de nuevos agentes antitumorales. El proyecto ToxAb permitir\u00e1 desarrollar nuevos ADCs con gran valor a\u00f1adido y mejor \u00edndice terap\u00e9utico que los utilizados actualmente.<\/p>\n

      Una de las tecnolog\u00edas de la Biomed divisi\u00f3n del Centro Tecnol\u00f3gico Leitat est\u00e1 basada en su amplia experiencia en la generaci\u00f3n y desarrollo de anticuerpos monoclonales para usos diagn\u00f3sticos y terap\u00e9uticos; as\u00ed como la capacidad de an\u00e1lisis de la eficacia terap\u00e9utica de nuevos f\u00e1rmacos en una gran variedad de modelos celulares in vitro y de modelos de crecimiento de tumor en animales.<\/p>\n

      Actualmente Leitat ha generado nuevos anticuerpos monoclonales para aplicaci\u00f3n terap\u00e9utica contra receptores transmembranales expresados en la superficie de c\u00e9lulas tumorales. La particularidad de estos anticuerpos reside en su doble especificidad ya que reconocen un ep\u00edtopo com\u00fan en Her1 y en Her2. Si bien existen anticuerpos en el mercado contra Her1 (Erbitux y Vectibix) y contra Her2 (Herceptin y Perjeta), hasta la fecha los \u00fanicos inhibidores duales contra Her1 y Her2 son mol\u00e9culas qu\u00edmicas de bajo peso molecular (lapatinib, neratinib, y afatinib). Estas mol\u00e9culas y sus buenos resultados terap\u00e9uticos en pacientes de distintos tipos tumorales abren la puerta a la aproximaci\u00f3n dual tambi\u00e9n en monoclonales. En este sentido, los nuevos anticuerpos generados por LEITAT representan un reflejo de estas necesidades. Adicionalmente, cabe considerar los efectos secundarios que han mostrado los mAbs contra Her1 (rash d\u00e9rmico) o los mAbs contra Her2 (problemas cardiovasculares) y que no se han descrito de manera cruzada. La especificidad dual de los nuevos mAbs permite suponer que el ep\u00edtopo reconocido no participa en ninguna de las patolog\u00edas y consecuentemente podr\u00edan ser mejor tolerados por los pacientes.<\/p>\n

      Adem\u00e1s, recientemente el grupo de investigaci\u00f3n de la Biomed Division de Leitat ha publicado el uso de hairpins de DNA (PPRH) contra survivina como agente de terapia g\u00e9nica para tumores de pr\u00f3stata, siendo esta estrategia extensible tambi\u00e9n a otros tumores.<\/p>\n

      La uni\u00f3n de los nuevos PPRH de Leitat contra survivina (para c\u00e1ncer de mama y colon) a los nuevos anticuerpos anti-Her1\/Her2 de Leitat mediante la innovadora tecnolog\u00eda de Proteo Design justifica el car\u00e1cter innovador del presente proyecto ToxAb. Adem\u00e1s, el proyecto se complementa tambi\u00e9n con la uni\u00f3n de mol\u00e9culas citot\u00f3xicas a los mismos anticuerpos. Finalmente, el proyecto contempla el an\u00e1lisis de la actividad terap\u00e9utica anti-c\u00e1ncer de los productos generados en los modelos celulares y en los modelos de crecimiento de tumor en ratones que dispone el centro Leitat.<\/p>\n

      \"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      El proyecto de investigaci\u00f3n aplicada ToxAb tiene por objetivo principal generar una ventaja competitiva en el \u00e1rea de la terapia oncol\u00f3gica mediante la validaci\u00f3n y el uso de la tecnolog\u00eda de conjugaci\u00f3n de agentes citot\u00f3xicos y material gen\u00e9tico (PPRHs) a anticuerpos monoclonales. Por tanto, el proyecto combina el potencial de tres l\u00edneas de investigaci\u00f3n punteras: […]<\/p>\n","protected":false},"author":3,"featured_media":5749,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[14],"tags":[25],"class_list":["post-5748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-technologies","tag-news"],"yoast_head":"\nInnovative Antibody Drug for cancer treatment<\/title>\n<meta name=\"description\" content=\"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS - Colaboraci\u00c3\u00b3n - 2014\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovative Antibody Drug for cancer treatment\" \/>\n<meta property=\"og:description\" content=\"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS - Colaboraci\u00c3\u00b3n - 2014\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/\" \/>\n<meta property=\"og:site_name\" content=\"Leitat Technological Center\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-15T14:32:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-10T11:30:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1129\" \/>\n\t<meta property=\"og:image:height\" content=\"619\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Comunicaci\u00f3n Leitat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Comunicaci\u00f3n Leitat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/\"},\"author\":{\"name\":\"Comunicaci\u00f3n Leitat\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\"},\"headline\":\"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS – Colaboraci\u00f3n 2014\",\"datePublished\":\"2015-07-15T14:32:01+00:00\",\"dateModified\":\"2025-02-10T11:30:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/\"},\"wordCount\":704,\"publisher\":{\"@id\":\"https:\/\/leitat.org\/es\/#organization\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png\",\"keywords\":[\"News\"],\"articleSection\":[\"Health technologies\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/\",\"url\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/\",\"name\":\"Innovative Antibody Drug for cancer treatment\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png\",\"datePublished\":\"2015-07-15T14:32:01+00:00\",\"dateModified\":\"2025-02-10T11:30:31+00:00\",\"description\":\"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS - Colaboraci\u00c3\u00b3n - 2014\",\"breadcrumb\":{\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png\",\"width\":1129,\"height\":619},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"HOME\",\"item\":\"https:\/\/leitat.org\/es\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health technologies\",\"item\":\"https:\/\/leitat.org\/es\/blog\/category\/health-technologies\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS – Colaboraci\u00f3n 2014\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/leitat.org\/es\/#website\",\"url\":\"https:\/\/leitat.org\/es\/\",\"name\":\"Leitat Technological Center\",\"description\":\"Managing Technologies\",\"publisher\":{\"@id\":\"https:\/\/leitat.org\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/leitat.org\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/leitat.org\/es\/#organization\",\"name\":\"Leitat Technological Center\",\"url\":\"https:\/\/leitat.org\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"width\":226,\"height\":78,\"caption\":\"Leitat Technological Center\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\",\"name\":\"Comunicaci\u00f3n Leitat\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"caption\":\"Comunicaci\u00f3n Leitat\"},\"sameAs\":[\"https:\/\/leitat.org\"],\"url\":\"https:\/\/leitat.org\/es\/blog\/author\/comunica-wp\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovative Antibody Drug for cancer treatment","description":"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS - Colaboraci\u00c3\u00b3n - 2014","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_ES","og_type":"article","og_title":"Innovative Antibody Drug for cancer treatment","og_description":"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS - Colaboraci\u00c3\u00b3n - 2014","og_url":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/","og_site_name":"Leitat Technological Center","article_published_time":"2015-07-15T14:32:01+00:00","article_modified_time":"2025-02-10T11:30:31+00:00","og_image":[{"width":1129,"height":619,"url":"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png","type":"image\/png"}],"author":"Comunicaci\u00f3n Leitat","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Comunicaci\u00f3n Leitat","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#article","isPartOf":{"@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/"},"author":{"name":"Comunicaci\u00f3n Leitat","@id":"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131"},"headline":"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS – Colaboraci\u00f3n 2014","datePublished":"2015-07-15T14:32:01+00:00","dateModified":"2025-02-10T11:30:31+00:00","mainEntityOfPage":{"@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/"},"wordCount":704,"publisher":{"@id":"https:\/\/leitat.org\/es\/#organization"},"image":{"@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png","keywords":["News"],"articleSection":["Health technologies"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/","url":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/","name":"Innovative Antibody Drug for cancer treatment","isPartOf":{"@id":"https:\/\/leitat.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage"},"image":{"@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png","datePublished":"2015-07-15T14:32:01+00:00","dateModified":"2025-02-10T11:30:31+00:00","description":"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS - Colaboraci\u00c3\u00b3n - 2014","breadcrumb":{"@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#primaryimage","url":"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2016\/03\/Toxcab.png","width":1129,"height":619},{"@type":"BreadcrumbList","@id":"https:\/\/leitat.org\/es\/blog\/toxab-innovative-antibody-drug-conjugates-adc-cancer-treatment-proyecto-retos-colaboracion-2014\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"HOME","item":"https:\/\/leitat.org\/es\/home\/"},{"@type":"ListItem","position":2,"name":"Health technologies","item":"https:\/\/leitat.org\/es\/blog\/category\/health-technologies\/"},{"@type":"ListItem","position":3,"name":"TOXAB : Innovative Antibody Drug Conjugates (ADC) for cancer treatment. Proyecto RETOS – Colaboraci\u00f3n 2014"}]},{"@type":"WebSite","@id":"https:\/\/leitat.org\/es\/#website","url":"https:\/\/leitat.org\/es\/","name":"Leitat Technological Center","description":"Managing Technologies","publisher":{"@id":"https:\/\/leitat.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leitat.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/leitat.org\/es\/#organization","name":"Leitat Technological Center","url":"https:\/\/leitat.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","width":226,"height":78,"caption":"Leitat Technological Center"},"image":{"@id":"https:\/\/leitat.org\/es\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/leitat.org\/es\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131","name":"Comunicaci\u00f3n Leitat","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","caption":"Comunicaci\u00f3n Leitat"},"sameAs":["https:\/\/leitat.org"],"url":"https:\/\/leitat.org\/es\/blog\/author\/comunica-wp\/"}]}},"_links":{"self":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/5748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/comments?post=5748"}],"version-history":[{"count":3,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/5748\/revisions"}],"predecessor-version":[{"id":42462,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/posts\/5748\/revisions\/42462"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/media\/5749"}],"wp:attachment":[{"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/media?parent=5748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/categories?post=5748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leitat.org\/es\/wp-json\/wp\/v2\/tags?post=5748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}